German Cancer Research Center (DE)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
184
Publications
2471
Citations
224835
i10-index
1008
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Improved Survival with Ipilimumab in Patients with... | 2010 | 15185 |
Combined Nivolumab and Ipilimumab or Monotherapy i... | 2015 | 8161 |
Improved Survival with Vemurafenib in Melanoma wit... | 2011 | 7743 |
The Immune Landscape of Cancer | 2018 | 5774 |
Nivolumab in Previously Untreated Melanoma without... | 2014 | 5410 |
Overall Survival with Combined Nivolumab and Ipili... | 2017 | 5348 |
Five-Year Survival with Combined Nivolumab and Ipi... | 2019 | 3712 |
An Integrated TCGA Pan-Cancer Clinical Data Resour... | 2018 | 3707 |
The repertoire of mutational signatures in human c... | 2020 | 3516 |
Oncogenic Signaling Pathways in The Cancer Genome ... | 2018 | 3193 |
Dirk Schadendorf is a researcher with 2471 publications and 224835 citations. They are affiliated with German Cancer Research Center. Their research focuses on . With an h-index of 184, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Dirk Schadendorf and 250M+ other papers.
Citations per publication by year